Is maternal use of selective serotonin reuptake inhibitors in the third trimester of pregnancy harmful to neonates?

CMAJ. Canadian Medical Association Journal

Volumn 172, Issue 11, 2005, Pages 1457-1459

  Koren, Gideon ^a,b,c   Matsui, Doreen ^c   Einarson, Adrienne ^b   Knoppert, David ^c   Steiner, Meir ^d  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b Ivey Chair in Molecular Toxicology   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; CLONAZEPAM; FLUOXETINE; FLUVOXAMINE; NORADRENALIN; PAROXETINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

CLINICAL FEATURE; CONFUSION; DIAPHORESIS; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FLUSHING; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERHIDROSIS; HYPERREFLEXIA; HYPERTHERMIA; INSOMNIA; IRRITABILITY; MOTOR COORDINATION; MYOCLONUS; NAUSEA; NOTE; PRENATAL EXPOSURE; RESPIRATORY DISTRESS; RESTLESSNESS; RISK FACTOR; SEROTONIN SYNDROME; SIDE EFFECT; THIRD TRIMESTER PREGNANCY; TREMOR; VERTIGO; VOMITING; WITHDRAWAL SYNDROME;

EID: 20444423361     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.1041100     Document Type: Note

References (19)

1. US Food and Drag Administration. FDA Medwatch Drug Alert on Effexor (venlafaxine HCl) and Effexor XR (venlafaxine HCl), 2004 June 3. Available: www .fda.gov/medwatch/safety/2004/safety04.htm#effexor (accessed 2005 Apr 25).
2. Health Canada advisory of potential adverse effects of SSRIs and other antidepressants on newborns. Aug 9, 2004. Health Canada Online. Available: www.hc-sc.gc.ca/english/protection/warnings/2004/2004_44.htm (accessed 2005 Apr 25).
3. Einarson A, Selby P, Koren G. Abrupt discontinuation of psychotropic drugs during pregnancy: fear of teratogenic risk and impact of counselling. J Psychiatry Neurosci 2001;26:44-8.
4. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996;335(14):1010-5.
5. Costei AM, Kozer E, Ho T, Ito S, Koren G. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med 2002;156(11): 1129-32.
6. Hendrick V, Smith LM, Suri R, Hwang S, Haynes D, Altshuler L. Birth outcomes after prenatal exposure to antidepressant medication. Am J Obstet Gynecol 2003;188(3):812-5.
7. Kallen B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 2004;158(4):312-6.
8. Oberlander TF, Misri S, Fitzgerald CE, Kostaras X, Rurak D, Riggs W. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J Clin Psychiatry 2004;65:230-7.
9. Sanz EJ, De-las-Cuevas C, Kiuru A, Bate A, Edwards R. Selective serotonin reuptake inhibitors in pregnant women and the neonatal withdrawal syndrome: a database analysis. Lancet 2005;365(9458):482-7.
10. Coupland NJ, Bell CJ, Potokar JP. Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol 1996;16:356-62.
11. Sternbach H. The serotonin syndrome [review]. Am J Psychiatry 1991;148:705-13.
12. Isbister GK, Bowe SJ, Dawson A, Whyte IM. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol 2005;42:277-85.
13. Misri S, Kim J, Riggs KW, Kostaras X. Paroxetine levels in postpartum depressed women, breast milk, and infant seram. J Clin Psychiatry 2000;61:828-32.
14. Laine K, Heikkinen T, Ekblad U, Kero P. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatr 2003;60:720-6.
15. Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 1998;44:77-87.
16. Newport DJ, Hostetter A, Arnold A, Stowe ZN. The treatment of postpartum depression: minimizing infant exposure [review]. J Clin Psychiatry 2002;63(Suppl 7):31-44.
17. Beck CT. Revision of the Postpartum Depression Predictors Inventory [review]. J Obstet Gynecol Neonatal Nurs 2002;31(4):394-402.
18. De Moor RA, Mourad L, ter Haar J, Egberts AC. [Withdrawal symptoms in a neonate following exposure to venlafaxine during pregnancy]. Ned Tijdschr Geneeskd 2003;147(28):1370-2.
19. Bonari L, Bennett H, Einarson A, Koren G. Risks of untreated depression in pregnancy. Can Fam Physician 2004;50:37-9.